Compare MEC & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | AMPH |
|---|---|---|
| Founded | 1945 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 885.7M | 971.8M |
| IPO Year | 2019 | 2005 |
| Metric | MEC | AMPH |
|---|---|---|
| Price | $35.78 | $20.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | $24.33 | ★ $28.38 |
| AVG Volume (30 Days) | ★ 666.6K | 626.5K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.14 |
| Revenue | N/A | ★ $719,887,000.00 |
| Revenue This Year | $10.65 | $6.90 |
| Revenue Next Year | $8.66 | $4.64 |
| P/E Ratio | ★ N/A | $146.64 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $12.10 | $16.65 |
| 52 Week High | $36.24 | $31.26 |
| Indicator | MEC | AMPH |
|---|---|---|
| Relative Strength Index (RSI) | 78.15 | 54.75 |
| Support Level | $17.20 | $18.92 |
| Resistance Level | N/A | $24.61 |
| Average True Range (ATR) | 2.09 | 0.72 |
| MACD | 0.49 | 0.31 |
| Stochastic Oscillator | 93.12 | 78.95 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.